11 Jefferies Group Protagonist Therapeutics Trades
Jefferies Group's position in Protagonist Therapeutics is currently worth $49.1M. That's 0.84% of their equity portfolio (24th largest holding). The investor owns 1.34% of the outstanding Protagonist Therapeutics stock. The first Protagonist Therapeutics trade was made in Q4 2022. Since then Jefferies Group bought shares five more times and sold shares on five occasions. The stake costed the investor $22.2M, netting the investor a gain of 121% so far.
Avg closing price
Price range
Increased shares by 30.4% (+192k shares)
Q2 2025
Avg closing price
$48.03
Price range
$40.89
-
$56.37
Sold 57.6% shares (-858k shares)
Q1 2025
Avg closing price
$41.70
Price range
$35.09
-
$59.76
Sold 17.9% shares (-325k shares)
Q4 2024
Avg closing price
$43.53
Price range
$38.51
-
$48.43
Sold 11.1% shares (-226k shares)
Q3 2024
Avg closing price
$40.35
Price range
$33.72
-
$47.33
Increased shares by 72.8% (+860k shares)
Q2 2024
Avg closing price
$29.29
Price range
$24.66
-
$34.80
Sold 7.1% shares (-90k shares)
Q1 2024
Avg closing price
$27.21
Price range
$21.79
-
$32.15
Increased shares by 52.1% (+435k shares)
Q4 2023
Avg closing price
$17.50
Price range
$14.05
-
$23.44
Increased shares by 9.9% (+75k shares)
Q3 2023
Avg closing price
$19.40
Price range
$16.68
-
$23.66
New holding (+761k shares)
Q2 2023
Avg closing price
$25.03
Price range
$18.02
-
$29.36
Sold -100k shares
Q1 2023
Avg closing price
$16.79
Price range
$10.78
-
$25.38
New holding (+100k shares)
Q4 2022
Avg closing price
$8.44
Price range
$7.36
-
$11.17
News about Protagonist Therapeutics Inc and Jefferies Group
Protagonist Therapeutics, Inc. Forecasted to Earn FY2021 Earnings of ($2.67) Per Share (NASDAQ:PTGX)
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock analysts at Jefferies Financial Group reduced their FY2021 earnings per share (EPS) estimates for Protago...